法定代表人辞任的，公司将在法定代表人辞任 之日起三十日内确定新的法定代表人。 修订前 修订后 第八条 总经理（总裁）为公司的法 第八条 总经理（总裁）为公司的法定代表人。 定代表人。 总经理（总裁）辞任的，视为同时辞去法定代 表人。 新增： 第九条 法定代表人以公司名义从事的民事活 动，其法律后果由公司承受。 本章程或者股东会对法定代表人职权的限制， 不得对抗善意相对人。 法定代表人因为执行职务造成他人损害的，由 公司承担民事责任。公司承担民事责任后，依照法 律或者本章程的规定，可以向有过错的法定代表人 追偿。 第 二十 一 条 公 司或 公 司的 子 公司 第二十二条 公司或者公司的子公司（包括公司 （包括公司的附属企业）不以赠与、垫资、 的附属企业）不以赠与、垫资、担保、借款等形式， 担保、补偿或贷款等形式，对购买或者拟 为他人取得本公司或者其母公司的股份提供财务资 购买公司股份的人提供任何资助。 助，公司实施员工持股计划的除外。 为公司利益，经股东会决议，或者董事会按照 本章程或者股东会的授权作出决议，公司可以为他 人取得本公司或者其母公司的股份提供财务资助， 但财务资助的累计总额不得超过已发行股本总额 ...

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-064 江苏吴中医药发展股份有限公司关于收到 中国证券监督管理委员会《行政处罚事先告知书》的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 江苏吴中医药发展股份有限公司（以下简称"公司"）于 2025 年 2 月 26 日收到中国证券监督管理委员会（以下简称"中国证监会"）《立案告知书》（证 监立案字 0392025006 号），因公司涉嫌信息披露违法违规，根据《中华人民共 和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公 司立案。具体内容详见公司于 2025 年 2 月 27 日披露的《关于收到中国证券监督 管理委员会立案告知书暨风险提示公告》（公告编号：临 2025-007）。 （公 告编号：临 2025-038），公司董事长因涉嫌信息披露违法违规，中国证监会决 定对其立案。 （处 *ST 苏吴子公司江苏吴中进出口有限公司、中吴贸易发展(杭州)有限公司、 江苏吴中海利国际贸易有限公司通过与浙江优诺德贸易有限公司等多家关联公 司开展 ...

■本报记者 王磊 "公司与农行从2017年开始合作，在农行和各大金融机构扶持下，公司发展步入'快车道'，目前正扩建 新厂区，开发参脉饮、四妙丸等药食同源的新产品，农行山西长治分行为公司发放1000万元贷款，有力 支持新产品开发。"郭玉轩说。 同样受益于农行支持的还有平顺县中药材种植大户韩小亮。韩小亮告诉记者，2023年，他回平顺县西沟 乡韩家村担任村支书，通过农行"晋品e贷——药材种植贷"，获得200万元信贷资金支持，用于扩大种植 规模和引进加工设备。如今，他的药材种植面积已从100亩扩大到200亩，年收入从20万元增长到35万 元，并带动周边70多户农户共同发展。 记者了解到，近年来，越来越多企业和种植户都得益于农行贷款支持。 农行长治分行相关负责人对记者表示，该分行把服务乡村振兴和实体经济作为主责主业，将支持当 地"特""优"产业振兴发展摆在重要位置，聚焦服务乡村振兴重点领域，助推乡村产业发展，建立健全现 代农业全产业链金融服务体系。针对平顺县中药材产业经营户现金交易多、流水反映不全面等无法有效 反映经营实况的现状，该分行充分利用"一项目一方案一授权"特殊支持政策，针对性制定《长治市平顺 县中药材产业集群 ...

云南产业链系列深度③，文章转自2025年07月04日太平洋医药团队报告，分析师：谭紫媚、 李啸岩 投资要点 中药市场快速增长，新品兑现蓄满成长动能。 在政策指引下，中药行业供给端、支付端、需求端利好措施不断，涵盖中药注册、审评审批、质量控制、医保支 付、中医药文化弘扬等方面，全方位促进中药行业的繁荣与发展。我国是世界上中药材资源最丰富、产量最大的国家之一，市场需求量持续稳定上升。2022年我 国中药材市场成交额达2085亿元，同比增长8.8%，预计2024年将达2357亿元。中游产成品市场规模约8000亿元，中成药占主要地位，中药饮片规模增速更快。根 据药融云数据库，2016-2023年，我国中药申请临床试验与获批临床试验数量呈上升的趋势。《基层中医药服务能力提升工程"十四五"行动计划》对中医药基层 渗透率提出要求，正值十四五收官之年，中医药基层渗透率有望快速提升。 云南为中药材主要供应地。 云南是全国中药资源最丰富的地区，中药材种植面积居全国第一。2023年云南中药材综合产值达1650亿元。全国药用生物资源12000 余种，云南省占比51%；全国常规种植中药材品种中，48%的品种在云南省种植；全国大宗药材品 ...

Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the Chinese medicine sector [6]. Core Insights - The Chinese medicine sector saw a 1.08% increase last week, with the overall pharmaceutical sector experiencing a general upward trend [2]. - The price-to-earnings (PE) ratio for the Chinese medicine sector is 27.86X, reflecting a slight increase, while the price-to-book (PB) ratio stands at 2.31X, also showing a minor rise [3]. - The market for Chinese medicinal materials is currently in a low season, with a slight decline in price indices due to increased rainfall in southern regions [4]. - As of July 12, 2025, three out of five listed companies in the Chinese medicine industry reported positive net profit growth, with the lowest growth rate at 24.3% [5]. Summary by Sections Market Performance - The Chinese medicine sector index closed at 6451.72 points, up 1.08% last week, while the overall pharmaceutical index rose by 1.82% [2][17]. Valuation - The PE ratio (ttm) for the Chinese medicine sector is 27.86X, up 0.29X week-on-week, with a one-year maximum of 30.13X and a minimum of 22.58X. The PB ratio (lf) is 2.31X, up 0.03X, with a one-year maximum of 2.65X and a minimum of 1.99X [3][19]. Industry Trends - The Chinese medicine sector is entering the mid-year reporting season, with a focus on performance metrics such as inventory and accounts receivable [5]. - The report highlights three main investment themes: price governance, consumption recovery, and state-owned enterprise reform, indicating potential growth areas within the sector [6][9]. Investment Recommendations - Recommended companies include those with strong R&D capabilities and unique products, as well as those less affected by price collection policies. Specific companies highlighted are Zhaoli Pharmaceutical, Pizaihuang, and Shouxiangu [10].

Summary of Key Points Core Viewpoint - Tai Long Pharmaceutical (600222) is planning to issue up to RMB 800 million in short-term financing bonds to replace bank loans and supplement working capital, with a shareholder meeting scheduled for July 17, 2025, to discuss this proposal [1]. Company Performance - As of July 11, 2025, Tai Long Pharmaceutical's stock closed at RMB 6.01, reflecting a 2.91% increase from the previous week's closing price of RMB 5.84 [1]. - The stock reached a weekly high of RMB 6.06 on July 10, 2025, and a low of RMB 5.81 on July 7, 2025 [1]. - The company's current total market capitalization is RMB 3.449 billion, ranking 51st out of 67 in the traditional Chinese medicine sector and 4016th out of 5149 in the A-share market [1]. Financing Plans - The company intends to apply for registration to issue short-term financing bonds with a maximum total of RMB 800 million, with individual bond terms not exceeding 270 days [1]. - The issuance will be conducted in a manner that allows for either a single or multiple issuances within the approved registration limit and validity period [1]. - The funds raised will be used for replacing financial institution loans and supplementing working capital [1]. - The interest rate for the bonds will be determined based on the company's credit rating and market interest rates [1]. - The management team will be authorized to handle the registration, issuance, and related tasks for the short-term financing bonds [1].

当前，高海鑫已接任公司法定代表人，这一安排被部分市场观点解读为推进 "去家族化" 的信号。 作者｜柯柏妮 康缘药业董事长肖伟的提前离任引发行业广泛关注。作为执掌企业近 25 年的核心管理者，其在公司业绩承压阶段的职务变动，使市场对企业后续发展态 势保持高度关注。这家曾在中药领域具有显著竞争力的企业，当前正面临多重挑战。 肖伟提前离任引关注 肖伟的离任日期为今年6月20日，其原定任期至2026年6月25日届满。 对于此次提前离任，公司公告称系"个人原因"，据内部信息显示年龄因素为重要考量，且肖伟后续将聚焦于公司战略规划、研发体系建设及接班人梯队培 养工作。 （转自：明见局） 从政策环境来看，2017年版国家医保药品目录对中药注射剂使用范围作出严格限定，热毒宁注射液被纳入 "限二级及以上医疗机构重症患者使用" 范围， 此后该产品销量呈现明显下滑趋势。 2023 年起，国家医保局深化"腾笼换鸟"机制，中药注射剂被纳入重点监控范畴，行业面临用药安全性方面的广泛讨论。 尽管热毒宁注射液未进入国家集中采购范围，但在地方集采（如江苏省）中价格降幅显著，2024年平均降价幅度达30%，直接影响产品利润空间。 银杏二萜内酯葡胺 ...

Core Viewpoint - The report highlights the performance and investment strategy of the Great Wall Healthcare Mixed Securities Investment Fund for the second quarter of 2025, emphasizing its focus on the healthcare industry and the fund's net value growth during the period [1][10]. Fund Overview - Fund Name: Great Wall Healthcare Mixed Fund - Fund Code: 000339 - Fund Type: Contractual open-end fund - Total Fund Shares at Period End: 117,458,484.44 shares - Investment Objective: Focus on listed companies in the healthcare industry, aiming for performance that exceeds the benchmark while controlling risks [1][2]. Investment Strategy - The fund employs a mixed investment strategy, adjusting asset allocation based on market conditions. It combines top-down and bottom-up approaches to analyze macroeconomic factors and the fundamentals of investable stocks [2][3]. - The healthcare sector includes various sub-industries such as pharmaceuticals, traditional Chinese medicine, biological products, medical services, and medical devices. The fund selects outstanding companies from these sub-industries for its stock portfolio [2][3]. Performance Benchmark - The performance benchmark is composed of 90% of the CSI Pharmaceutical and Health Index return and 10% of the China Bond Composite Wealth Index return [3]. Risk and Return Characteristics - The fund is characterized by a long-term average risk and expected return that is lower than equity funds but higher than bond and money market funds, categorizing it as a high-risk, high-return product [3]. Financial Performance - The net value growth rate of the Great Wall Healthcare Mixed Fund A for the past three months was 17.49%, while the benchmark return was 1.41% [10]. - Over the past six months, the fund's growth rate was 2.23%, compared to a benchmark return of 32.19% [10]. - The fund's performance over the past year showed a net value growth rate of 35.19%, with a benchmark return of 10.13% [10]. Investment Composition - As of the report period, the fund's total assets included approximately 265,126,026.09 yuan in stocks, accounting for 71.42% of the total fund assets [11]. - The fund's investment strategy mandates that at least 80% of its non-cash assets be invested in stocks of listed companies in the healthcare sector [6]. Fund Management - The fund manager, Great Wall Fund Management Co., Ltd., has adhered to relevant laws and regulations, ensuring the fair treatment of different investors and maintaining a disciplined investment approach [7][9].

Meeting Information - The company will hold its first extraordinary general meeting of shareholders for 2025 on July 29, 2025, at 16:00 [1] - Shareholders can vote through both on-site and online platforms, with specific time slots for online voting [2][4] Voting Procedures - Shareholders must choose either on-site or online voting, and duplicate votes will be counted as the first vote [2] - Only shareholders registered by the cut-off date of July 22, 2025, can attend and vote at the meeting [2][3] Agenda Items - The meeting will discuss several proposals, including: - Increasing the company's registered capital and amending the articles of association [3] - Modifications to various internal governance documents, including the rules for shareholder meetings and board meetings [3][12] - Election of the eighth board of directors, including both independent and non-independent directors [3][12] Voting Requirements - Certain proposals require a special resolution, needing more than two-thirds of the voting rights present, while others require a simple majority [4] - Cumulative voting will be used for the election of directors, allowing shareholders to allocate their votes among candidates [4][12] Registration and Contact Information - Shareholders must register for the meeting by July 28, 2025, and can contact the company for assistance [5][6]

| 证券简称：珍宝岛 公告编号：临 | 2025-052 | | | 证券代码：603567 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 黑龙江珍宝岛药业股份有限公司 | | | | | | | | | 关于控股股东部分股份解质押及再质押的公告 | | | | | | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 | | | | | | | | | 漏，并对其内容的真实性、准确性和完整性承担法律责任。 | | | | | | | | | 重要内容提示: | | | | | | | | | ? 黑龙江珍宝岛药业股份有限公司（以下简称"公司"或"珍宝岛"）控股 | | | | | | | | | 股东黑龙江创达集团有限公司（以下简称"创达集团"）因可交换公司债券换股， | | | | | | | | | 57,637.9841 万股无限售流通股，占公司总股本 | | | | 截至本公告披露日持有公司股份 | | | | | 61.24%。创达集团未间接持有公司股份，无一致行动人。 | | | | ...